1.53  0 (0%)		08-18 16:00
Open: 1.52 High: 1.559 Volume: 3,368,964		Pre. Close: 1.53 Low: 1.51 Market Cap: 982(M)

Short term
Mid term
Targets	6-month :	1.92	1-year :	2.25
Resists	First :	1.64	Second :	1.92
Pivot price	1.47
Supports	First :	1.38	Second :	1.22
MAs	MA(5) :	1.52	MA(20) :	1.46
	MA(100) :	1.42	MA(250) :	1.39
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	67.4	D(3) :	68.7
RSI	RSI(14): 54.6
52-week	High :	2	Low :	1.03

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ GERN ] has closed below upper band by 37.0%. Bollinger Bands are 33.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.56 - 1.57	1.57 - 1.58
Low:	1.48 - 1.5	1.5 - 1.51
Close:	1.51 - 1.53	1.53 - 1.54

Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.

Tue, 18 Aug 2026
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Tue, 18 Aug 2026
Geron Corp.: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis - Seeking Alpha

Fri, 14 Aug 2026
Geron Stock Price Forecast. Should You Buy GERN? - StockInvest.us

Fri, 14 Aug 2026
RA Capital reports 66.5M-share Geron (GERN) position capped at 9.99% ownership - Stock Titan

Fri, 14 Aug 2026
Geron (NASDAQ:GERN) Stock Price Down 5.2% - Here's Why - MarketBeat

Thu, 13 Aug 2026
GERN|Geron Corp|Price:1.530|Chg%:-0.040 - TradingKey

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	642 (M)
Shares Float	537 (M)
Held by Insiders	0 (%)
Held by Institutions	81.4 (%)
Shares Short	69,920 (K)
Shares Short P.Month	74,850 (K)

EPS	-0.11
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.36
Profit Margin	-33.1 %
Operating Margin	-22.1 %
Return on Assets (ttm)	-4.2 %
Return on Equity (ttm)	-28.3 %
Qtrly Rev. Growth	17.2 %
Gross Profit (p.s.)	0.18
Sales Per Share	0.31
EBITDA (p.s.)	-0.06
Qtrly Earnings Growth	0 %
Operating Cash Flow	-114 (M)
Levered Free Cash Flow	-78 (M)

PE Ratio	-13.91
PEG Ratio	0
Price to Book value	4.24
Price to Sales	4.79
Price to Cash Flow	-8.59

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.